Guardian Pharmacy Services (NYSE:GRDN) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Guardian Pharmacy Services (NYSE:GRDN) from a hold rating to a buy rating in a research report report published on Saturday,Wall Street Zen reports.

A number of other research firms have also recently commented on GRDN. Oppenheimer lifted their price objective on Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Weiss Ratings upgraded shares of Guardian Pharmacy Services from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. KeyCorp assumed coverage on shares of Guardian Pharmacy Services in a report on Tuesday, September 22nd. They issued an “overweight” rating and a $52.00 target price on the stock. Finally, Truist Financial raised their price target on shares of Guardian Pharmacy Services from $47.00 to $51.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.57.

Guardian Pharmacy Services Stock Performance

Guardian Pharmacy Services stock opened at $40.28 on Friday. Guardian Pharmacy Services has a fifty-two week low of $25.01 and a fifty-two week high of $48.33. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of 39.11, a PEG ratio of 2.06 and a beta of 0.03. The stock has a fifty day moving average of $40.81 and a two-hundred day moving average of $39.91.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.03. Guardian Pharmacy Services had a return on equity of 29.97% and a net margin of 4.50%. The business had revenue of $351.77 million for the quarter, compared to the consensus estimate of $340.45 million. On average, analysts forecast that Guardian Pharmacy Services will post 1.18 EPS for the current fiscal year.

Hedge Funds Weigh In On Guardian Pharmacy Services

Large investors have recently bought and sold shares of the stock. State of Alaska Department of Revenue grew its stake in shares of Guardian Pharmacy Services by 105.9% during the 3rd quarter. State of Alaska Department of Revenue now owns 2,390 shares of the company’s stock valued at $97,000 after buying an additional 1,229 shares during the period. Elevation Point Wealth Partners LLC acquired a new stake in shares of Guardian Pharmacy Services during the 1st quarter worth $253,000. Stephens Inc. AR acquired a new stake in shares of Guardian Pharmacy Services during the 1st quarter worth $282,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Guardian Pharmacy Services in the 2nd quarter worth $335,000. Finally, Arizona State Retirement System raised its position in shares of Guardian Pharmacy Services by 53.0% in the 2nd quarter. Arizona State Retirement System now owns 8,393 shares of the company’s stock worth $351,000 after buying an additional 2,907 shares during the period.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc (NYSE: GRDN) is a healthcare services company that provides pharmacy services to residents of long-term care and other institutional healthcare settings. Its customers include assisted living communities, skilled nursing facilities, behavioral health centers and communities serving individuals with developmental disabilities.

The company’s services include prescription dispensing, medication packaging and delivery, medication management, pharmacy consulting and clinical support.